ID   NCI-H774
AC   CVCL_1589
SY   H774; H-774
DR   CLO; CLO_0008116
DR   ATCC; CRL-5842
DR   BioSample; SAMN03472967
DR   cancercelllines; CVCL_1589
DR   Cosmic; 801618
DR   Cosmic; 844562
DR   Cosmic; 844809
DR   Cosmic; 876163
DR   Cosmic; 924243
DR   Cosmic; 1006530
DR   Cosmic; 1090400
DR   Cosmic; 1152478
DR   Cosmic; 1219105
DR   Cosmic; 1759297
DR   Cosmic; 2125258
DR   GEO; GSM1887921
DR   GEO; GSM1888003
DR   IARC_TP53; 438
DR   PRIDE; PXD011896
DR   Wikidata; Q54908122
RX   PubMed=1312696;
RX   PubMed=1565469;
RX   PubMed=8626706;
RX   PubMed=8806092;
RX   PubMed=8806103;
RX   PubMed=9331070;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=11030152;
RX   PubMed=20164919;
RX   PubMed=25877200;
RX   PubMed=27247353;
RX   PubMed=28766886;
RX   PubMed=31803961;
RX   PubMed=32586373;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:6844; MAP2K4; Zygosity=Homozygous (PubMed=9331070).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469; PubMed=10536175).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; miRNA profiling; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Soft tissue; UBERON=UBERON_0034929.
ST   Source(s): ATCC=CRL-5842; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 12
ST   D18S51: 14,17
ST   D19S433: 13,14
ST   D21S11: 31.2
ST   D2S1338: 23,24
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 12,13
ST   FGA: 20
ST   Penta D: 14
ST   Penta E: 7,12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 28
//
RX   PubMed=1312696;
RA   D'Amico D., Carbone D.P., Mitsudomi T., Nau M.M., Fedorko J.,
RA   Russell E., Johnson B., Buchhagen D.L., Bodner S.M., Phelps R.M.,
RA   Gazdar A.F., Minna J.D.;
RT   "High frequency of somatically acquired p53 mutations in small-cell
RT   lung cancer cell lines and tumors.";
RL   Oncogene 7:339-346(1992).
//
RX   PubMed=1565469;
RA   Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P.,
RA   Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F.,
RA   Linnoila R.I.;
RT   "Expression of mutant p53 proteins in lung cancer correlates with the
RT   class of p53 gene mutation.";
RL   Oncogene 7:743-749(1992).
//
RX   PubMed=8626706; DOI=10.1074/jbc.271.19.11477;
RA   Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M.,
RA   Grimley C., Battey J., Mulshine J.L., Cuttitta F.;
RT   "Insulin-like growth factor expression in human cancer cell lines.";
RL   J. Biol. Chem. 271:11477-11483(1996).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. Suppl. 24:32-91(1996).
//
RX   PubMed=8806103; DOI=10.1002/jcb.240630516;
RA   Johnson B.E., Russell E., Simmons A.M., Phelps R.M., Steinberg S.M.,
RA   Ihde D.C., Gazdar A.F.;
RT   "MYC family DNA amplification in 126 tumor cell lines from patients
RT   with small cell lung cancer.";
RL   J. Cell. Biochem. Suppl. 24:210-217(1996).
//
RX   PubMed=9331070;
RA   Teng D.H.-F., Perry W.L. 3rd, Hogan J.K., Baumgard M.L., Bell R.,
RA   Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R.,
RA   Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R.,
RA   Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M.,
RA   Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A.,
RA   Skolnick M.H., Tavtigian S.V.;
RT   "Human mitogen-activated protein kinase kinase 4 as a candidate tumor
RT   suppressor.";
RL   Cancer Res. 57:4177-4182(1997).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27247353; DOI=10.1093/jnci/djw122; PMCID=PMC6279282;
RA   Polley E.C., Kunkel M.W., Evans D., Silvers T.E., Delosh R.M., Laudeman J.,
RA   Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Fer N.,
RA   Sonkin D., Kaur G., Monks A., Malik S., Morris J., Teicher B.A.;
RT   "Small cell lung cancer screen of oncology drugs, investigational
RT   agents, and gene and microRNA expression.";
RL   J. Natl. Cancer Inst. 108:djw122.1-djw122.11(2016).
//
RX   PubMed=28766886; DOI=10.1002/cam4.1131; PMCID=PMC5548882;
RA   Teicher B.A., Silvers T.E., Selby M., Delosh R.M., Laudeman J., Ogle C.,
RA   Reinhart R., Parchment R.E., Krushkal J., Sonkin D., Rubinstein L.,
RA   Morris J., Evans D.;
RT   "Small cell lung carcinoma cell line screen of etoposide/carboplatin
RT   plus a third agent.";
RL   Cancer Med. 6:1952-1964(2017).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564; PMCID=PMC7496084;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=32586373; DOI=10.1186/s13148-020-00876-8; PMCID=PMC7318526;
RA   Krushkal J., Silvers T.E., Reinhold W.C., Sonkin D., Vural S.,
RA   Connelly J., Varma S., Meltzer P.S., Kunkel M.W., Rapisarda A.,
RA   Evans D., Pommier Y., Teicher B.A.;
RT   "Epigenome-wide DNA methylation analysis of small cell lung cancer
RT   cell lines suggests potential chemotherapy targets.";
RL   Clin. Epigenetics 12:93.1-93.28(2020).
//